NEW ENGLAND HEALTHCARE EXECUTIVE NETWORK MEETING

JUNE 6, 2019, 7:30AM TO 10:00AM

MERGERS & AQUISITION
PATH TO EXIT, SOURCE OF GROWTH
REGISTER HERE

OUR MEETING SPACE IS BEING PROVIDED BY DEVICETALKS 2019

SEAPORT WORLD TRADE CENTER, 1 SEAPORT LN, BOSTON, MA 02210

FOR DRIVING AND PARKING INFORMATION, CLICK HERE

Program Description

Mergers and acquisitions (M&A) are a vital part of the business life cycle for heath technology companies. The opportunities, challenges, and risks both for companies considering an exit and for companies seeking to grow through acquisition are the topic of this event.

Amar Sawhney, Chairman of Ocular Therapeutics, is the keynote speaker. Amar will share his experiences building and exiting multiple successful companies.

Companies that have successfully established themselves with customers and material revenues must decide whether their goals can be achieved by growing independently or exiting.

Larger med tech companies see entrepreneurial companies as a lower risk R&D feeder channel for their growth. The larger companies can more quickly take the innovative products to scale than the smaller companies can on their own.

Following Mr. Sawhney’s remarks, a panel will share their experiences going through the M&A process. The panel includes entrepreneurs, CEOs and Corporate Business Development Executives: Martha Shadan, Miach Orthopaedics; Peter Stebbins, JNJ;….

Keynote Speaker

Amar Sawhney, Ph.D., Chairman, Ocular Therapeutix

Amar is the co-founder of the company and Augmenix, an affiliate of Ocular Therapeutix, recently acquired by Boston Scientific.  Previously, Dr. Sawhney founded Confluent Surgical and served as its President and CEO prior to its acquisition by Covidien. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of Access Closure, Inc., acquired by Cardinal Health.

Moderator

Rick Williams, Managing Director, Williams Advisory Partners

Rick is a technology company board member, CEO and board advisor. Nationally published thought leader on preparing to raise capital, overcoming barriers to growth and preparing for the sale of the company.

Panelists

Charlie Attlan, Senior VP, Corporate Strategy & Business Development, Boston Scientific

Charlie’s team is responsible for corporate strategic planning as well as coordinating the identification, assessment and execution of business development transactions including acquisitions, VC/minority investments, divestitures, licensing deals, co-development agreements and joint ventures.

Eric Knudsen, VP, Business Development, ZOLL Medical

Eric is responsible for all of ZOLL’s strategic investments, merger and acquisition activities.

Martha Shadan, President and CEO, Miach Orthopaedics

Martha Shadan has more than three decades of experience in the life science industry as a business leader in a variety of both large and start-up organizations.

Peter Stebbins, VP, Business Development, Johnson & Johnson

Peter is based at the Boston Johnson & Johnson Innovation Center in Kendall Square.  His background and remit covers a range of medtech deals from early stage partnerships through L&A with VC-backed and public companies to divestitures and externalizations.

Come join this timely, lively, keynote presentation and blue-ribbon panel discussion. Ask questions and contribute your insights during the audience interactive segment.

What to Expect

The M&A process offers opportunity and risk for both the acquiring company and the leaders and owners of the firms being acquired. The panel will address these topics among others:

  • What should a company be doing to make themselves into an attractive acquisition candidate?
  • What factors should a company be balancing when deciding whether to grow independently or seek an exit partner?
  • What are the factors a firm considering an acquisition values in a potential target company?
  • Many acquisitions do not reach the financial targets. What usually goes wrong?
  • What should the owners and leaders of a company being acquired try to achieve or make sure does not happen?

Who should attend:

C-level executives, board members, investors, and other senior leaders who want a better understanding of how to make important decisions at strategic inflection points for the company.

Speaker Bios

Charlie Attlan, Senior VP, Corporate Strategy & Business Development, Boston Scientific

Charlie currently serves as Senior Vice President, Corporate Strategy and Business Development for Boston Scientific. He joined the company in 2010 and his team is responsible for corporate strategic planning as well as coordinating the identification, assessment and execution of business development transactions including acquisitions, VC/minority investments, divestitures, licensing deals, co-development agreements and joint ventures. Boston Scientific has been amongst the most active investors in medical technology over the past 10 years, having completed over 35 acquisitions across size ranges from sub $10 million to several $ billions, as well as growing our venture capital portfolio to over 30 investments across strategic areas of interest. Charlie received a Bachelor of Arts in Economics from Princeton University.

Eric Knudsen, VP, Business Development, ZOLL Medical

Eric is responsible for ZOLL’s strategic investment, merger and acquisition activities. Since joining ZOLL in 2013, Eric has helped the company close on over 10 mergers or acquisitions and added several companies to its corporate venture portfolio.

Prior to joining ZOLL Eric held positions in business development, international sales, and marketing with Covidien, Aspect Medical Systems, and LeMaitre Vascular. Having lived and worked overseas Eric has managed strategic partnerships, licensing agreements and acquisitions in over 30 countries. He sits on the board of directors of Miracor Medical, a Belgium based, clinical-stage company developing solutions to treat heart damage after acute myocardial infarction.

Eric holds an MBA from the Thunderbird School of Global Management and a bachelor’s degree in political science and communication from Boston College.

Amar Sawhney, Ph.D., Chairman, Ocular Therapeutix

Amarpreet Sawhney, Ph.D., was elected as Executive Chairman of the Board in July 2017. Since co-founding the company in 2006, he served as President and Chief Executive Officer until 2017. Dr. Sawhney was also the CEO of Augmenix, an affiliate of Ocular Therapeutix, from 2008 until April 2014. In addition, he is a general partner of Incept, LLC, an intellectual property holding company. Previously, Dr. Sawhney founded Confluent Surgical and served as its President and CEO prior to its acquisition by Covidien plc. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of Access Closure, Inc., acquired by Cardinal Health in 2014. Dr. Sawhney’s innovations are the subject of over 100 issued and pending patents. He holds M.S. and Ph.D. degrees in Chemical Engineering from the University of Texas at Austin, as well as a B.Tech. in Chemical Engineering from the Indian Institute of Technology, Delhi India.

Martha Shadan, President and CEO, Miach Orthopaedics

Martha Shadan joined Miach Orthopaedics as the president and chief executive officer in January 2019.  During 2018, Shadan served as global vice president of marketing at Smith & Nephew plc, a role she assumed after the company acquired Rotation Medical, where she was president and CEO. Shadan led Rotation Medical through FDA approval and commercialization of the Rotation Medical Bioinductive Implant for rotator cuff tears (now known as REGENETEN), as well as the company’s acquisition by Smith & Nephew in December 2017.

Martha Shadan has more than three decades of experience in the life science industry as a business leader in a variety of both large and start-up organizations.  Prior to joining Rotation Medical, Martha was the president of the Trauma Division at Zimmer where she managed the P&L for the global business. Martha served at Covidien as vice president/general manager of Vascular Therapies and vice president/general manager BioSurgery and Sports Surgery. Other companies that have benefited from Martha’s experience and leadership include Bristol Myers Squibb Co. and Merck Millipore.

Martha is the chairwoman of the Board of Directors for a medical device start-up, IlluminOss. She is actively involved with the Advanced Medical Technology Association (AdvaMed), serving on the Board of Directors since 2017; being a member of the Accel Board of Directors since 2015 and currently serving as its chairwoman.   Accel is the division within AdvaMed dedicated to addressing the unique needs and challenges of smaller medical technology manufacturers.  Martha chairs the Diversity and Inclusion Committee for AdvaMed and is a founding member of the Leadership Circle for the Women’s Executive Network (WEN).  She is also a board advisor for several other companies.

Martha holds a Master of Business Administration from Northeastern University, Master of Science in biology from Michigan State University, and Bachelor of Science in biology from the University of New Hampshire.

Peter Stebbins, VP, Business Development, Johnson & Johnson

Peter is Vice President of Business Development, operating from the Johnson & Johnson Innovation Center in Boston, focused on medical devices.

Peter has had a career of challenging innovation-centered roles in operations, sales, marketing, international, business development, strategy and investment partnerships. His most recent major deal was the divestiture of the Advanced Sterilization Products business for $2.7B.  At the Innovation Center, he executed six early stage deals across vision, sealants, hemostats, orthopedics, 3DP and advanced imaging/robotics.   Prior to the Innovation Center, he was VP of Strategy for DePuy Synthes Orthopedics  GOC & Business Development for Codman Neuro.

Before that, Peter held senior roles on the Management Boards of Mitek Sports Medicine and Codman Neuro – often nurturing relationships with startups and their physician advisors over several years as their innovation gestated to the point of licensing, JJDC investment or acquisition.  He helped reposition and grow Mitek from purely shoulder anchors to arthroscopy-enabling approaches and to early intervention, exemplified by Orthovisc and Monovisc HA injections for OA.  At Codman Neuro, he helped redefine their business by divesting the Instruments business and the Neurosurgery business and emphasizing neurovascular stroke intervention, exemplified by Micrus, Pulsar and Neuravi acquisitions.

Peter spent the first half of his career in the Ethicon Surgery businesses.

Peter studied Chemical Engineering at Princeton on an ROTC scholarship before serving with US Army in West Germany and entering Harvard Business School. He is on the Board of Directors of both MassMEDIC and the HBS Healthcare Alumni Association.

Rick Williams, Managing Director, Williams Advisory Partners

Rick is Managing Director of Williams Advisory Partners, LLC. He has a breadth of experience as an executive and board director for technology companies including medical technology and financial services. Williams Advisory Partners provides CEO and board advisory services for middle market technology companies. Rick founded and was President of The Equity Company, an award winning multifamily real estate investment and development company. He was Chairman of the Board of Point Care Technologies and formerly was Chairman of a quasi-public bank/VC firm providing financing to companies with limited access to conventional financing. Rick is past President of the Harvard Business School Association of Boston. He was a management consultant with the global consulting firm Arthur D. Little, Inc., working on business strategy and acquisitions and the economic and strategic impact of government policy and regulations on a broad spectrum of industries. Before that, he was a physicist with Itek Corp, where he developed space and defense related photo & electro/optical systems.